Clinical Significance of Serum GPC-3 and PSA in Detection of Patients with Prostatic Cancer
CHEN Tao
QIU Jian-hong
LIU Jian
Abstract：Objective To explore the clinical significance of serum glypican-3 (GPC-3) and prostate specific antigen ( PSA) in detection of patients with prostatic cancer. Methods A total of 35 cases of prostatic cancer, 100 cases of benign prostatic hyperplasia and 30 healthy controls between August 2014 and June 2015 were included in the study. Serum levels of GPC-3 and PSA were detected by ELISA and RIA, then the cure of the receiver operating characteristics ( ROC) was drawn, and test results of GPC-3, tPSA, fPSA and fPSA/tPSA were compared. Results The difference of serum GPC-3 in patients with prostatic cancer, benign prostatic hyperplasia and healthy people were statistically significant (P<0. 01). ROC showed that the sensitivity and specificity of GPC-3 alone were 69. 4% and 94. 3% respectively, and the sensitivity and specificity of GPC-3 joint tPSA detection were 91. 5% and 87. 6% respectively. Conclusion The co-detection of GPC-3 with PSA can make up for the lack of PSA alone, and improve the accuracy of prostatic cancer detection.
Keywords：Prostatic neoplasmProstatic hyperplasiaProstate-specific antigenGlypicanDiagnosis
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 105-107 )